Lonapegsomatropin not checked
Ascendis Pharma Endocrinology Division A/S · ACP-011
FollowEvery change as it happens, and a Monday email
Trials
5 active
7 in total · 2 in the EU
Targets
—
None known yet
What this is
- How it works
- Recombinant Human Growth Hormone FDA class
- How it’s given
- “Administered as two separate SC injections. Treatment duration of up to 52 weeks of navepegritide and placebo for lonapegsomatropin followed by 52 weeks of navepegritide and lonapegsomatropin.”In the company’s words, NCT07924059 on ClinicalTrials.gov
- Tested for
- Turner Syndrome (2 trials), Achondroplasia (2 trials), Short Stature Homeobox Gene Mutation, Idiopathic Short Stature, Small for Gestational Age at Delivery
- Main trialPhase 3
- “This basket trial will enroll prepubertal children and adolescents with clinically diagnosed and genetically confirmed (if applicable) TS, SHOX-D, SGA, or ISS between ages of ≥2 and \<18 years with open growth plates. The purpose of the study is to see how well treatment with once-weekly lonapegsomatropin works compared to treatment with daily somatropin. Approximately 186 participants will be distributed equally (1:1), to receive either lonapegsomatropin for 2 years or somatropin for 1 year followed by lonapegsomatropin for 1 year. This trial will be conducted in the United States, France,…”In the company’s words, NCT07221851 on ClinicalTrials.gov
- Other names
- ACP-011
Other drugs for Turner Syndrome
- InpegsomatropinXiamen Amoytop Biotech Co., Ltd. · Phase 3
- SomapacitanNovo Nordisk · Phase 3
Coming up2
- Feb 2028Phase 3 trial completes · ClinicalTrials.gov
- Sep 2028Phase 3 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 9 NovNew trial: none to Phase 3 · ClinicalTrials.gov NCT07924059
Trials7
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Feb 2028 | Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders | |
| Phase 3Not yet recruiting | Sep 2028 | Clinical Trial Evaluating the Efficacy and Safety of Navepegritide and Lonapegsomatropin in Achondroplasia | |
| Phase 2Active, not recruiting | 18 Oct 2024 | A Trial to Investigate Different Doses of Lonapegsomatropin Compared to Somatropin in Individuals With Turner Syndrome | |
| Phase 2Active, not recruiting | 14 Nov 2025 | A Phase 2 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of Navepegritide in Combination With Lonapegsomatropin in Children With Achondroplasia | |
| Phase 3Completed | 2 Nov 2023 | A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency | |
| Phase 3Completed | 23 Dec 2024 | A Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone Deficiency | |
| Phase 3Authorised | not given | HighLiGHts - A Pivotal, Parallel-Arm, Phase 3, Open-Label, Active-controlled, Global, Multicenter, Randomized Basket Trial Investigating the Efficacy and Safety of Once-weekly Lonapegsomatropin Compared to Daily Somatropin in Prepubertal Children and Adolescents with Growth Failure or Short Stature due to Growth Hormone Sufficient Disorders – Turner Syndrome, SHOX Deficiency, Small for Gestational Age, and Idiopathic Short Stature |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026